Report Detail
Global Myasthenia Gravis Drugs Market Professional Survey Report 2019
- RnM3754042 |
- 17 September, 2019 |
- Global |
- 112 Pages |
- QYResearch |
- Pharma & Healthcare
Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance.
The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market’s growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal antibodies, as they act specifically on target cells; thereby, leading to lower side effects. Since conventional therapies such as acetylcholinesterase inhibitor, oral steroids, and immunomodulatory agents are associated with more side effects, physicians prefer to prescribe high efficacious monoclonal antibodies.
The global Myasthenia Gravis Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Myasthenia Gravis Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Myasthenia Gravis Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Myasthenia Gravis Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Myasthenia Gravis Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Flamel Technologies
Roche
Grifols
Pfizer
Shire
Novartis
Valeant
Alexion
Catalyst
CSL
Curavac
Cytokinetics
Galencia
GlaxoSmithKline
Lupin Pharmaceuticals
Mitsubishi Tanabe Pharma
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Anticholinesterases
Immunosuppressants
Intravenous Immune Globulins
Segment by Application
Hospitals
Clinics
Table of Contents
Executive Summary
1 Industry Overview of Myasthenia Gravis Drugs
- 1.1 Definition of Myasthenia Gravis Drugs
- 1.2 Myasthenia Gravis Drugs Segment by Type
- 1.2.1 Global Myasthenia Gravis Drugs Production Growth Rate Comparison by Types (2014-2025)
- 1.2.2 Anticholinesterases
- 1.2.3 Immunosuppressants
- 1.2.4 Intravenous Immune Globulins
- 1.3 Myasthenia Gravis Drugs Segment by Applications
- 1.3.1 Global Myasthenia Gravis Drugs Consumption Comparison by Applications (2014-2025)
- 1.3.2 Hospitals
- 1.3.3 Clinics
- 1.4 Global Myasthenia Gravis Drugs Overall Market
- 1.4.1 Global Myasthenia Gravis Drugs Revenue (2014-2025)
- 1.4.2 Global Myasthenia Gravis Drugs Production (2014-2025)
- 1.4.3 North America Myasthenia Gravis Drugs Status and Prospect (2014-2025)
- 1.4.4 Europe Myasthenia Gravis Drugs Status and Prospect (2014-2025)
- 1.4.5 China Myasthenia Gravis Drugs Status and Prospect (2014-2025)
- 1.4.6 Japan Myasthenia Gravis Drugs Status and Prospect (2014-2025)
- 1.4.7 Southeast Asia Myasthenia Gravis Drugs Status and Prospect (2014-2025)
- 1.4.8 India Myasthenia Gravis Drugs Status and Prospect (2014-2025)
2 Manufacturing Cost Structure Analysis
- 2.1 Raw Material and Suppliers
- 2.2 Manufacturing Cost Structure Analysis of Myasthenia Gravis Drugs
- 2.3 Manufacturing Process Analysis of Myasthenia Gravis Drugs
- 2.4 Industry Chain Structure of Myasthenia Gravis Drugs
3 Development and Manufacturing Plants Analysis of Myasthenia Gravis Drugs
- 3.1 Capacity and Commercial Production Date
- 3.2 Global Myasthenia Gravis Drugs Manufacturing Plants Distribution
- 3.3 Major Manufacturers Technology Source and Market Position of Myasthenia Gravis Drugs
- 3.4 Recent Development and Expansion Plans
4 Key Figures of Major Manufacturers
- 4.1 Myasthenia Gravis Drugs Production and Capacity Analysis
- 4.2 Myasthenia Gravis Drugs Revenue Analysis
- 4.3 Myasthenia Gravis Drugs Price Analysis
- 4.4 Market Concentration Degree
5 Myasthenia Gravis Drugs Regional Market Analysis
- 5.1 Myasthenia Gravis Drugs Production by Regions
- 5.1.1 Global Myasthenia Gravis Drugs Production by Regions
- 5.1.2 Global Myasthenia Gravis Drugs Revenue by Regions
- 5.2 Myasthenia Gravis Drugs Consumption by Regions
- 5.3 North America Myasthenia Gravis Drugs Market Analysis
- 5.3.1 North America Myasthenia Gravis Drugs Production
- 5.3.2 North America Myasthenia Gravis Drugs Revenue
- 5.3.3 Key Manufacturers in North America
- 5.3.4 North America Myasthenia Gravis Drugs Import and Export
- 5.4 Europe Myasthenia Gravis Drugs Market Analysis
- 5.4.1 Europe Myasthenia Gravis Drugs Production
- 5.4.2 Europe Myasthenia Gravis Drugs Revenue
- 5.4.3 Key Manufacturers in Europe
- 5.4.4 Europe Myasthenia Gravis Drugs Import and Export
- 5.5 China Myasthenia Gravis Drugs Market Analysis
- 5.5.1 China Myasthenia Gravis Drugs Production
- 5.5.2 China Myasthenia Gravis Drugs Revenue
- 5.5.3 Key Manufacturers in China
- 5.5.4 China Myasthenia Gravis Drugs Import and Export
- 5.6 Japan Myasthenia Gravis Drugs Market Analysis
- 5.6.1 Japan Myasthenia Gravis Drugs Production
- 5.6.2 Japan Myasthenia Gravis Drugs Revenue
- 5.6.3 Key Manufacturers in Japan
- 5.6.4 Japan Myasthenia Gravis Drugs Import and Export
- 5.7 Southeast Asia Myasthenia Gravis Drugs Market Analysis
- 5.7.1 Southeast Asia Myasthenia Gravis Drugs Production
- 5.7.2 Southeast Asia Myasthenia Gravis Drugs Revenue
- 5.7.3 Key Manufacturers in Southeast Asia
- 5.7.4 Southeast Asia Myasthenia Gravis Drugs Import and Export
- 5.8 India Myasthenia Gravis Drugs Market Analysis
- 5.8.1 India Myasthenia Gravis Drugs Production
- 5.8.2 India Myasthenia Gravis Drugs Revenue
- 5.8.3 Key Manufacturers in India
- 5.8.4 India Myasthenia Gravis Drugs Import and Export
6 Myasthenia Gravis Drugs Segment Market Analysis (by Type)
- 6.1 Global Myasthenia Gravis Drugs Production by Type
- 6.2 Global Myasthenia Gravis Drugs Revenue by Type
- 6.3 Myasthenia Gravis Drugs Price by Type
7 Myasthenia Gravis Drugs Segment Market Analysis (by Application)
- 7.1 Global Myasthenia Gravis Drugs Consumption by Application
- 7.2 Global Myasthenia Gravis Drugs Consumption Market Share by Application (2014-2019)
8 Myasthenia Gravis Drugs Major Manufacturers Analysis
- 8.1 Flamel Technologies
- 8.1.1 Flamel Technologies Myasthenia Gravis Drugs Production Sites and Area Served
- 8.1.2 Flamel Technologies Product Introduction, Application and Specification
- 8.1.3 Flamel Technologies Myasthenia Gravis Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.1.4 Main Business and Markets Served
- 8.2 Roche
- 8.2.1 Roche Myasthenia Gravis Drugs Production Sites and Area Served
- 8.2.2 Roche Product Introduction, Application and Specification
- 8.2.3 Roche Myasthenia Gravis Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.2.4 Main Business and Markets Served
- 8.3 Grifols
- 8.3.1 Grifols Myasthenia Gravis Drugs Production Sites and Area Served
- 8.3.2 Grifols Product Introduction, Application and Specification
- 8.3.3 Grifols Myasthenia Gravis Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.3.4 Main Business and Markets Served
- 8.4 Pfizer
- 8.4.1 Pfizer Myasthenia Gravis Drugs Production Sites and Area Served
- 8.4.2 Pfizer Product Introduction, Application and Specification
- 8.4.3 Pfizer Myasthenia Gravis Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.4.4 Main Business and Markets Served
- 8.5 Shire
- 8.5.1 Shire Myasthenia Gravis Drugs Production Sites and Area Served
- 8.5.2 Shire Product Introduction, Application and Specification
- 8.5.3 Shire Myasthenia Gravis Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.5.4 Main Business and Markets Served
- 8.6 Novartis
- 8.6.1 Novartis Myasthenia Gravis Drugs Production Sites and Area Served
- 8.6.2 Novartis Product Introduction, Application and Specification
- 8.6.3 Novartis Myasthenia Gravis Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.6.4 Main Business and Markets Served
- 8.7 Valeant
- 8.7.1 Valeant Myasthenia Gravis Drugs Production Sites and Area Served
- 8.7.2 Valeant Product Introduction, Application and Specification
- 8.7.3 Valeant Myasthenia Gravis Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.7.4 Main Business and Markets Served
- 8.8 Alexion
- 8.8.1 Alexion Myasthenia Gravis Drugs Production Sites and Area Served
- 8.8.2 Alexion Product Introduction, Application and Specification
- 8.8.3 Alexion Myasthenia Gravis Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.8.4 Main Business and Markets Served
- 8.9 Catalyst
- 8.9.1 Catalyst Myasthenia Gravis Drugs Production Sites and Area Served
- 8.9.2 Catalyst Product Introduction, Application and Specification
- 8.9.3 Catalyst Myasthenia Gravis Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.9.4 Main Business and Markets Served
- 8.10 CSL
- 8.10.1 CSL Myasthenia Gravis Drugs Production Sites and Area Served
- 8.10.2 CSL Product Introduction, Application and Specification
- 8.10.3 CSL Myasthenia Gravis Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.10.4 Main Business and Markets Served
- 8.11 Curavac
- 8.12 Cytokinetics
- 8.13 Galencia
- 8.14 GlaxoSmithKline
- 8.15 Lupin Pharmaceuticals
- 8.16 Mitsubishi Tanabe Pharma
9 Development Trend of Analysis of Myasthenia Gravis Drugs Market
- 9.1 Global Myasthenia Gravis Drugs Market Trend Analysis
- 9.1.1 Global Myasthenia Gravis Drugs Market Size (Volume and Value) Forecast 2019-2025
- 9.2 Myasthenia Gravis Drugs Regional Market Trend
- 9.2.1 North America Myasthenia Gravis Drugs Forecast 2019-2025
- 9.2.2 Europe Myasthenia Gravis Drugs Forecast 2019-2025
- 9.2.3 China Myasthenia Gravis Drugs Forecast 2019-2025
- 9.2.4 Japan Myasthenia Gravis Drugs Forecast 2019-2025
- 9.2.5 Southeast Asia Myasthenia Gravis Drugs Forecast 2019-2025
- 9.2.6 India Myasthenia Gravis Drugs Forecast 2019-2025
- 9.3 Myasthenia Gravis Drugs Market Trend (Product Type)
- 9.4 Myasthenia Gravis Drugs Market Trend (Application)
- 10.1 Marketing Channel
- 10.1.1 Direct Marketing
- 10.1.2 Indirect Marketing
- 10.3 Myasthenia Gravis Drugs Customers
11 Market Dynamics
- 11.1 Market Trends
- 11.2 Opportunities
- 11.3 Market Drivers
- 11.4 Challenges
- 11.5 Influence Factors
12 Conclusion
13 Appendix
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Summary:
Get latest Market Research Reports on Myasthenia Gravis Drugs. Industry analysis & Market Report on Myasthenia Gravis Drugs is a syndicated market report, published as Global Myasthenia Gravis Drugs Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Myasthenia Gravis Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
